Dr. Andrés José María Ferreri

Specialised Oncologist

Hodgkin’s Lymphoma – Non Hodgkin’s Lymphoma – Chronic lymphocytic leukemia – Cerebral, Testicular, mediastinal, gastric lymphomas – Lymphomas related to HIV (AIDS) infections

The modern treatment of lymphomas is complex but extremely efficient and versatile. We have drugs capable of selectively targeting tumour cells and the molecular mechanisms that allow their development without harming healthy tissues. Nowadays, every patient and lymphoma is targeted with a specific treatment, that is better tolerated and more effective for that patient. The development of new drugs against lymphomas has become so rapid that new centres of excellence and organisational strategies have been developed to test the new drugs. This global need requires well-designed experimental studies that are conducted following high-level clinical and scientific standards. Today, we cannot deny a tailored treatment for patients affected by lymphoma.

– Andrés José María Ferreri –

IRCCS San Raffaele Hospital in Milan, Italy (since 1993)

– Director of the Lymphoma Unit at the San Raffaele Hospital in Milan

– Clinical Group Leader in the Experimental Oncology Division for Lymphoid Tumours at the San Raffaele Hospital in Milan

Clinical and Research activity

Dr. Andrés José María Ferreri performs clinical research on lymphomas, with a particular focus on the lymphomas of the central nervous system (brain, meninges, eyes), of the stomach and intestine, the testicles, mediastinum, liver and many other organs. There are currently many studies on indolent lymphomas such as of MALT, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia and lymphoma in small lymphocites, but also on aggressive lymphomas such as those present in patients affected by HIV (AIDS), Burkitt’s Lymphoma, “double expressor” lymphomas and “double hpit” and mantle cell lymphoma.

Dr. Andrés José María Ferreri has participated in the development of innovative treatments such as those with antibiotics and immune-modulators that avoid the use of chemotherapy and/or radiotherapy especially in the case of weak and at high-risk patients. In particular, his team has specialised in the development of etiopathogenic antibiotic therapies for eye lymphomas, Chlamydia psittaci or hepatitis C virus. Dr. Ferreri has defined the standard chemo-immune-therapeutic treatments adopted globally for patients affected by primitive and secondary lymphomas of the central nervous system.

Doctor Ferreri has won different Grants for research projects from the Associazione Italiana Ricerca sul Cancro, Ricerca Svizzera contro il cancro, Istituto Superiore di Sanità, Oncosuisse Collaborative Cancer Research and Fondazione San Romanello del Monte Tabor.

Awards and recognitions

2004 – PAUL HARRIS FELLOW of the Rotatory International Foundation:
“as a symbol of appreciation and recognition for his tangible and significant contribution in promoting a better comprehension among people from all over the world”

2010 – BEST PAPER AWARD 2010 of the San Raffaele Scientific Institute: “High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial”.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti, G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Lancet 374 (9700): 1512-20, 2009.

2011 – Certificate of Merit from the Comune di Milano Ambrogino d’Oro.

2015 – BEST PAPER AWARD 2015 of the San Raffaele Scientific Institute: “High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: Final results of a Multicenter Phase II trial.” Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D’Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F. Journal of Clinical Oncology 33(33):3903-3910, 2015.

Academic Experience and Roles

– Professor on Contract in Hematology specialty school, Università Vita e Salute of the San Raffaele Scientific Institute in Milan (since 2009)

– Faculty of the University Master on Diagnosis and treatment of patients with lymphoma at University of Udine (since 2012)

– Teaching assistant in Haematology at the School of Medicine, Università Vita e Salute of the San Raffaele Scientific Institute in Milan (since 2013)

– Professor on Contract in Hematology for the International MD Program at the Università Vita e Salute, San Raffaele Scientific Institute in Milan (since 2013)

– Director of the Oncology course for the International MD Program at the Università Vita e Salute, San Raffaele Scientific Institute in Milan (since 2013)

– Lecturer in the Certificate of Competence in Lymphoma at the European School of Oncology and Ulm University (from 2013 to 2014)

– Professor on contract of Oncology at the school of Dentistry of Università Vita e Salute of the San Raffaele Scientific Institute in Milan (since 2014)

Other activities

Dr. Ferreri is Founder of Fondazione Italiana Linfomi, the main organism in Italy that is occupied in the design, production and publication of clinical studies in this field.

He is also creator, founder and member of “Corpo dei Direttori dell’International Extranodal Lymphoma Study Group“, main scientific organisation involved in non-Hodgkin lymphomas; in this group Dr. Ferreri covers the role of Chairman for the team specialised in nervous system, eyes and orbits lymphomas.

Education and Training

– In 1985 Degree in Medicine, Facultad de Medicina de la Universidad de Buenos Aires.

– In 1992 Degree in Medicine. Facoltà di Medicina e Chirurgia, Università degli Studi di Parma.

– In 1989 Specialist in Clinical Oncology. Catedra de Oncologia Clinica y Quimioterapia Antineoplasica, Hospital Militar Central in Buenos Aires.

– In 2005 Specialist in Clinical Oncology at Università degli Studi di Milano.

Registered with the Certified Order of Doctors Albo dei Medici

Registered with the Certified Medical Association “Albo dei Medici" in Milan, n. 32046

Medical Career and Medical Memberships

– Training for Specialist in Clinical Oncology. Central Military Hosp. Buenos Aires, Argentina (from 1987 to 1989)

– Fellow- Divisions of Experimental Oncology and Medical Oncology, Istituto Nazionale dei Tumori, Milano (from 1987 to 1989)

– Fellow- Divisions of Radiochemotherapy of San Raffaele Scientific Institute, Milan (from 1994 to 1998)

– Researcher- Division of Radiochemotherapy of San Raffaele Scientific Institute, Milan (from 1998 to 2004)

– Unit Coordinator-Medical Oncology Unit of San Raffaele Scientific Institute, Milan (from 2004 to 2007)

– Deputy Director of the Medical Oncology Unit, Department of Oncology of San Raffaele Scientific Institute, Milan (from 2007 to 2010)

– Director of the Unit of Lymphoid Malignancies; Department of Oncology of San Raffaele Scientific Institute, Milan (since 2008)

– Deputy director of the Division of Onco-Hematological Medicine, Department of Onco-Hematology of San Raffaele Scientific Institute, Milan (since 2011)

– Founder member of Fondazione Italiana Linfomi FIL

– Certified member of European Society for Medical Oncology ESMO

– Probational Member of European Organization for Research and Treatment of Cancer EORTC, Lymphoma Group

– Member of American Society of Clinical Oncology ASCO

– International Member of American Society of Hematology ASH

– Faculty of European School of Oncology ESO

– Member of Società Italiana di Ematologia SIE

– Member of European Hematology Association EHA

– Member of Associazione Italiana di Oncologia Medica AIOM

Languages

Italian – English – Spanish

Treated cancer diseases

Hodgkin’s Lymphoma

Non Hodgkin’s Lymphoma

Chronic lymphocytic leukemia

Cerebral, Testicular, mediastinal, gastric lymphomas

Lymphomas related to HIV (AIDS) infections

San Raffaele Hospital
Oncology Division
Via Olgettina 60
20132 Milan, Italy


Contact

Per prenotare una visita ambulatoriale in libera professione:

Per prenotare una visita ambulatoriale tramite SSN: +39 02 26432643


Online Medical Consultation with Dr. Andrés José María Ferreri

Author and co-author of more than 300 scientific publications selected by Pubmed and available on Researchgate.

His papers and publications are available on renowned international scientific journals such as the The Lancet, The Lancet Oncology, The Lancet Haematology, Journal of Clinical Oncology, Journal of the National Cancer Institute, Blood, Annals of Oncology, Leukemia, Neurology, Ophthalmology, Critical Reviews in Oncology and Hematology, Cancer Treatment Reviews, Haematologica, British Journal of Haematology, British Journal of Cancer, Current Opinion in Oncology, Seminars in Cancer Biology, Clinical Cancer Research, European Journal of Cancer, International Journal of Cancer, Hematology and Oncology Clinics of North America, Hematological Oncology, Leukemia and Lymphoma, Annals of Hematology, Expert Opinion in Pharmacotherapy, International Journal of Immunopharmacology, The Oncologist, International Journal of Radiation Oncology Biology and Physics, Expert Reviews in Anticancer Therapy, Cancer Investigation, The American Journal of Surgical Pathology, Oncology, Journal of Neuro-Oncology, Nature Reviews in Clinical Oncology, Cancer, Journal of Chemotherapy, Hybridoma, Lung Cancer, Expert Review in Anticancer Research, The Hematology Journal, Journal of Pathology, Expert Reviews in Neurotherapeutics, Modern Pathology, Cancer Epidemiology Biomarkers Prevention, Radiotherapy & Oncology, Clinical Lymphoma & Myeloma, Histopathology, Cancer Letters, Clinical Cancer Research, Nature Clinical Practice Oncology, Anticancer Drugs, Human Pathology, Expert Reviews in Ophthalmology, Radiology, Chest, Basic and Clinical Pharmacology and Toxicology, Best Practice Research Clinical Haematology, British Journal of Clinical Pharmacology.

Reviser of scientific papers for important scientific journals on Oncology, Ematology, Internal Medicine and pathological anatomy.

Publications

Disruption of hmgA by DNA Duplication is Responsible for Hyperpigmentation in a Vibrio anguillarum Strain.
Batallones V, Fernandez J, Farthing B, Shoemaker J, Qian KL, Phan K, Fung E, Rivera A, Van K, de la Cruz F, Ferreri AJ, Burinski K, Zhang J, Lizarraga V, Doan K, Rocha K, Traglia G, Ramirez MS, Tolmasky ME.
Sci Rep. 2019 Oct 10;9(1):14589. doi: 10.1038/s41598-019-51126-8.

Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus G, Issa S, Schorb E, Zucca E, Hemkens LG, Schandelmaier S, Kasenda B.
Hematol Oncol. 2019 Aug 16. doi: 10.1002/hon.2666.

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group.
Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643.

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N.
Blood. 2019 Jul 18;134(3):252-262. doi: 10.1182/blood.2019000633.

Targeted therapies make room, anti-CD79b agents are coming.
Ferreri AJM.
Lancet Oncol. 2019 Jul;20(7):898-900. doi: 10.1016/S1470-2045(19)30182-2.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.
Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5.

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.
Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439.

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Rattotti S, Ferretti VV, Rusconi C, Rossi A, Fogazzi S, Baldini L, Pioltelli P, Balzarotti M, Farina L, Ferreri AJM, Laszlo D, Speziale V, Varettoni M, Sciarra R, Morello L, Tedeschi A, Frigeni M, Defrancesco I, Zerbi C, Flospergher E, Nizzoli ME, Morra E, Arcaini L; “Rete Ematologica Lombarda” (REL – Hematology Clinical Network of Lombardy – Lymphoma Workgroup).
Hematol Oncol. 2019 Apr;37(2):160-167. doi: 10.1002/hon.2575.

MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
Miserocchi E, Ferreri AJM, Giuffrè C, Cangi MG, Francaviglia I, Calimeri T, Ponzoni M, Pecciarini L, Bandello FM, Modorati GM.
Retina. 2019 Apr;39(4):679-684. doi: 10.1097/IAE.0000000000002319.

Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT.
Neuro Oncol. 2019 Feb 19;21(3):296-305. doi: 10.1093/neuonc/noy192.

Evolving Treatments for Primary Central Nervous System Lymphoma.
Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:454-466. doi: 10.1200/EDBK_242547.

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C.
Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641.

Clarithromycin as a “repurposing drug" against MALT lymphoma.
Ferreri AJM, Cecchetti C, Kiesewetter B, Sassone M, Calimeri T, Perrone S, Ponzoni M, Raderer M.
Br J Haematol. 2018 Sep;182(6):913-915. doi: 10.1111/bjh.14878.

ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients.
Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members.
Ann Oncol. 2018 Aug 1;29(8):1687-1700. doi: 10.1093/annonc/mdy167.

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A, Stathis A, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E.
Blood. 2018 Jul 12;132(2):179-186. doi: 10.1182/blood-2018-01-826958.

Seeking solutions to old problems in elderly patients with lymphoma.
Ferreri AJM.
Lancet Haematol. 2018 Jun;5(6):e235-e236. doi: 10.1016/S2352-3026(18)30065-6.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.
Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002.

Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma.
Citterio G, Calimeri T, Ferreri AJM.
Expert Rev Neurother. 2018 Apr 16:1-15. doi: 10.1080/14737175.2018.1462700.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.
Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.
J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652.

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A.
J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543.

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.
Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M.
Hematol Oncol. 2018 Feb;36(1):68-75. doi: 10.1002/hon.2425.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.
Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222.

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.
Ferreri AJM.
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):565-577. doi: 10.1182/asheducation-2017.1.565.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.
Visco C, Wang J, Tisi MC, Deng L, D’Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.
Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6.

Secondary CNS lymphoma: the poisoned needle in the haystack.
Ferreri AJM.
Ann Oncol. 2017 Oct 1;28(10):2335-2337. doi: 10.1093/annonc/mdx515.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.
Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009.

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Giovanella L, Zucca E, Johnson PWM.
Br J Haematol. 2017 Aug;178(4):588-591. doi: 10.1111/bjh.14728.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.
J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Jul 10;35(20):2342.

m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T, Ferreri AJM.
Br J Haematol. 2017 Jun;177(5):684-702. doi: 10.1111/bjh.14529.

Primary central nervous system lymphoma.
Citterio G, Reni M, Gatta G, Ferreri AJM.
Crit Rev Oncol Hematol. 2017 May;113:97-110. doi: 10.1016/j.critrevonc.2017.03.019.

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M.
Lancet Haematol. 2017 Mar;4(3):e137-e146. doi: 10.1016/S2352-3026(17)30016-9.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.
Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243.

Bacteria associated with marginal zone lymphomas.
Ponzoni M, Ferreri AJ.
Best Pract Res Clin Haematol. 2017 Mar – Jun;30(1-2):32-40. doi: 10.1016/j.beha.2017.01.001.

Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment.
Sassone M, Ponzoni M, Ferreri AJ.
Best Pract Res Clin Haematol. 2017 Mar – Jun;30(1-2):118-130. doi: 10.1016/j.beha.2016.11.002.

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
Ceriani L, Martelli M, Gospodarowicz MK, Ricardi U, Ferreri AJ, Chiappella A, Stelitano C, Balzarotti M, Cabrera ME, Cunningham D, Guarini A, Zinzani PL, Giovanella L, Johnson PW, Zucca E.
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):42-49. doi: 10.1016/j.ijrobp.2016.09.031.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.
Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.
Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.
Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.
J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980.

Chronic lymphocytic leukaemia.
Scarfò L, Ferreri AJ, Ghia P.
Crit Rev Oncol Hematol. 2016 Aug;104:169-82. doi: 10.1016/j.critrevonc.2016.06.003.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH.
Clin Cancer Res. 2016 Jul 15;22(14):3593-605. doi: 10.1158/1078-0432.CCR-15-2296.

The role of whole brain radiation in primary CNS lymphoma.
Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT.
Blood. 2016 Jul 7;128(1):32-6. doi: 10.1182/blood-2016-01-650101.

How we diagnose and treat vitreoretinal lymphoma.
Fend F, Ferreri AJ, Coupland SE.
Br J Haematol. 2016 Jun;173(5):680-92. doi: 10.1111/bjh.14025. Epub 2016 May 2. Review. Erratum in: Br J Haematol. 2018 Jun;181(5):712.

Reply to A. Korfel et al.
Ferreri AJ, Tarella C, Ciceri F.
J Clin Oncol. 2016 May 20;34(15):1830-1. doi: 10.1200/JCO.2016.66.4722.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma–a randomized phase III trial (MATRix).
Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G.
BMC Cancer. 2016 Apr 21;16:282. doi: 10.1186/s12885-016-2311-4.

The role of autologous stem cell transplantation in primary central nervous system lymphoma.
Ferreri AJ, Illerhaus G.
Blood. 2016 Mar 31;127(13):1642-9. doi: 10.1182/blood-2015-10-636340.

Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Raderer M, Kiesewetter B, Ferreri AJ.
CA Cancer J Clin. 2016 Mar-Apr;66(2):153-71. doi: 10.3322/caac.21330.

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH.
Aging (Albany NY). 2016 Feb;8(2):345-65.

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Dybkær K, Chiu A, Perry AM, Zhang S, Tzankov A, Rao H, Abramson J, Sohani AR, Xu M, Hsi ED, Zhu J, Ponzoni M, Wang S, Li L, Zhang M, Ferreri AJ, Parsons BM, Li Y, Piris MA, Medeiros LJ, Young KH.
Leukemia. 2016 Feb;30(2):361-72. doi: 10.1038/leu.2015.237.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.
Oncotarget. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Zhao X, Winter JN, Piris MA, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH.
Mod Pathol. 2015 Dec;28(12):1555-73. doi: 10.1038/modpathol.2015.118.

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D’Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F.
J Clin Oncol. 2015 Nov 20;33(33):3903-10. doi: 10.1200/JCO.2015.61.1236.

Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome.
Caliò A, Zamò A, Ponzoni M, Zanolin ME, Ferreri AJ, Pedron S, Montagna L, Parolini C, Fraifeld VE, Wolfson M, Yanai H, Pizzolo G, Doglioni C, Vinante F, Chilosi M.
Clin Cancer Res. 2015 Nov 15;21(22):5164-72. doi: 10.1158/1078-0432.CCR-15-0508.

Who Is Who in Primary Vitreoretinal Lymphoma?
Ferreri AJ.
JAMA Oncol. 2015 Oct;1(7):977-8. doi: 10.1001/jamaoncol.2015.1223.

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, O’Malley DP, Medeiros LJ, Young KH.
Mod Pathol. 2015 Oct;28(10):1297-314. doi: 10.1038/modpathol.2015.94.

Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH.
Oncotarget. 2015 Sep 15;6(27):23157-80.

Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH.
Mod Pathol. 2015 Sep;28(9):1202-13. doi: 10.1038/modpathol.2015.76.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E.
Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474.

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.
Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M.
Ann Oncol. 2015 Aug;26(8):1760-5. doi: 10.1093/annonc/mdv214.

Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.
Kiesewetter B, Ferreri AJ, Raderer M.
Oncologist. 2015 Aug;20(8):915-25. doi: 10.1634/theoncologist.2015-0109.

First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)–a systematic review and individual patient data meta-analysis.
Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O’Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M.
Ann Oncol. 2015 Jul;26(7):1305-13. doi: 10.1093/annonc/mdv076.

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma.
Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5.

Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH.
Oncotarget. 2015 Jun 10;6(16):14720.

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH.
Oncotarget. 2015 Jun 10;6(16):13933-45.

The Orbit and the Brain: Cheek by Jowl or Very Far Away?
Ferreri AJ.
JAMA Ophthalmol. 2015 Jun;133(6):726-7. doi: 10.1001/jamaophthalmol.2015.0365.

Primary central nervous system lymphoma: three linked questions in the situation puzzle of radiotherapy.
Ferreri AJ.
Leuk Lymphoma. 2015 May;56(5):1185-7. doi: 10.3109/10428194.2014.971411.

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH.
Oncotarget. 2015 Mar 20;6(8):5615-33. Erratum in: Oncotarget. 2015 Jun 10;6(16):14720. Nagarajan, Lalitha [Added].

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J, Xu-Monette ZY, Deng L, Shen Q, Manyam GC, Martinez-Lopez A, Zhang L, Montes-Moreno S, Visco C, Tzankov A, Yin L, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Pham L, Young KH.
Oncotarget. 2015 Mar 20;6(8):5597-614.

Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.
Br J Haematol. 2015 Mar;168(5):654-62. doi: 10.1111/bjh.13194.

Primary and secondary bone lymphomas.
Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ.
Cancer Treat Rev. 2015 Mar;41(3):235-46. doi: 10.1016/j.ctrv.2015.02.001.

Gamma-delta t-cell lymphomas.
Foppoli M, Ferreri AJ.
Eur J Haematol. 2015 Mar;94(3):206-18. doi: 10.1111/ejh.12439.

Present and future treatment options for primary CNS lymphoma.
Citterio G, Reni M, Ferreri AJ.
Expert Opin Pharmacother. 2015;16(17):2569-79. doi: 10.1517/14656566.2015.1088828.

Bendamustine plus rituximab in MALT lymphoma.
Ferreri AJ.
Lancet Haematol. 2014 Dec;1(3):e88-9. doi: 10.1016/S2352-3026(14)00023-4.

In reply.
Ferreri AJ, Gospodarowicz M, Zucca E, Christie D.
Oncologist. 2014 Dec;19(12):1289-90. doi: 10.1634/theoncologist.2014-0232.

Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH.
Clin Cancer Res. 2014 Oct 1;20(19):5113-23. doi: 10.1158/1078-0432.CCR-14-0683.

The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).
Govi S, Christie D, Mappa S, Marturano E, Bruno-Ventre M, Messina C, Medina EA, Porter D, Radford J, Heo DS, Park Y, Pro B, Jayamohan J, Pavlakis N, Zucca E, Gospodarowicz M, Ferreri AJ; International Extranodal Lymphoma Study Group.
Leuk Lymphoma. 2014 Aug;55(8):1796-9. doi: 10.3109/10428194.2013.853298.

De-escalating therapy in gastric aggressive lymphoma.
Cuccurullo R, Govi S, Ferreri AJ.
World J Gastroenterol. 2014 Jul 21;20(27):8993-7. doi: 10.3748/wjg.v20.i27.8993.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.
Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d’Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A.
Ann Oncol. 2014 Jul;25(7):1404-10. doi: 10.1093/annonc/mdu166.

Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
Conconi A, Raderer M, Franceschetti S, Devizzi L, Ferreri AJ, Magagnoli M, Arcaini L, Zinzani PL, Martinelli G, Vitolo U, Kiesewetter B, Porro E, Stathis A, Gaidano G, Cavalli F, Zucca E.
Br J Haematol. 2014 Jul;166(1):69-76. doi: 10.1111/bjh.12845.

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ferreri AJ, Ye Q, Winter JN, Farnen JP, Piris MA, Møller MB, You MJ, McDonnell T, Medeiros LJ, Young KH.
Mod Pathol. 2014 Jul;27(7):958-71. doi: 10.1038/modpathol.2013.214.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW.
J Clin Oncol. 2014 Jun 10;32(17):1769-75. doi: 10.1200/JCO.2013.51.7524.

Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, Møller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH.
Clin Cancer Res. 2014 May 1;20(9):2338-49. doi: 10.1158/1078-0432.CCR-13-3157. Epub 2014 Feb 28. Erratum in: Clin Cancer Res. 2014 Sep 15;20(18):4974. Dybaer, Karen [corrected to Dybkaer, Karen].

MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
Ferreri AJ, Ciceri F, Brandes AA, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Reni M.
Neurology. 2014 Apr 15;82(15):1370-3. doi: 10.1212/WNL.0000000000000314.

Risk of CNS dissemination in extranodal lymphomas.
Ferreri AJ.
Lancet Oncol. 2014 Apr;15(4):e159-69. doi: 10.1016/S1470-2045(13)70568-0.

Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use.
Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri AJ, Salar A, Rattotti S, Carpaneto A, Perez R, Bello JL, Hernandez M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group (SMZLSG).
Leuk Lymphoma. 2014 Apr;55(4):929-31. doi: 10.3109/10428194.2013.818143.

Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, Scarfò L, Zucca E, Gospodarowicz M, Christie D; International Extranodal Lymphoma Study Group (I.E.L.S.G.).
Br J Haematol. 2014 Mar;164(6):834-40. doi: 10.1111/bjh.12714.

Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).
Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, Radford J, Heo DS, Park Y, Martinelli G, Taylor E, Lucraft H, Hong A, Scarfò L, Zucca E, Christie D; International Extranodal Lymphoma Study Group.
Oncologist. 2014 Mar;19(3):291-8. doi: 10.1634/theoncologist.2013-0249.

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo FD, Carella AM, Micol Q, Balzarotti M, Musto P, Federico M.
Ann Oncol. 2014 Feb;25(2):442-7. doi: 10.1093/annonc/mdt562.

Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type.
Thieblemont C, Bertoni F, Copie-Bergman C, Ferreri AJ, Ponzoni M.
Semin Cancer Biol. 2014 Feb;24:33-42. doi: 10.1016/j.semcancer.2013.11.005.

Intravascular large B cell lymphoma: widespread but not everywhere.
Ponzoni M, Ferreri AJ.
Acta Haematol. 2014;131(1):16-7. doi: 10.1159/000354817.

The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone.
Govi S, Christie D, Messina C, Bruno Ventre M, Gracia Medina EA, Porter D, Radford J, Seog Heo D, Park Y, Martinelli G, Taylor E, Lucraft H, Ballova V, Zucca E, Gospodarowicz M, Ferreri AJ; International Extranodal Lymphoma Study Group (I.E.L.S.G.).
Ann Oncol. 2014 Jan;25(1):176-81. doi: 10.1093/annonc/mdt482.

Marginal zone lymphomas and infectious agents.
Ferreri AJ, Govi S, Ponzoni M.
Semin Cancer Biol. 2013 Dec;23(6):431-40. doi: 10.1016/j.semcancer.2013.09.004.

Current uses of radiation therapy in patients with primary CNS lymphoma.
Citterio G, Ferreri AJ, Reni M.
Expert Rev Anticancer Ther. 2013 Nov;13(11):1327-37. doi: 10.1586/14737140.2013.851007. Epub 2013 Oct 23.

Stem cell mobilization in HIV seropositive patients with lymphoma.
Re A, Cattaneo C, Skert C, Balsalobre P, Michieli M, Bower M, Ferreri AJ, Hentrich M, Ribera JM, Allione B, Schommers P, Montoto S, Almici C, Ferremi P, Mazzucato M, Gattillo S, Casari S, Spina M, Diez-Martin JL, Tirelli U, Rossi G; Cooperative European Group on AIDS and Tumors.
Haematologica. 2013 Nov;98(11):1762-8. doi: 10.3324/haematol.2013.089052.

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH.
Blood. 2013 Oct 10;122(15):2630-40. doi: 10.1182/blood-2012-12-473702.

Ten years of international primary CNS lymphoma collaborative group studies.
Ferreri AJ, Zucca E, Armitage J, Cavalli F, Batchelor TT.
J Clin Oncol. 2013 Sep 20;31(27):3444-5. doi: 10.1200/JCO.2013.51.7557.

Bendamustine salvage therapy for T cell neoplasms.
Zaja F, Baldini L, Ferreri AJ, Luminari S, Grossi A, Salvi F, Zambello R, Goldaniga M, Volpetti S, Fanin R.
Ann Hematol. 2013 Sep;92(9):1249-54. doi: 10.1007/s00277-013-1746-9.

The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach.
Ferreri AJ, Govi S, Ponzoni M.
Curr Opin Oncol. 2013 Sep;25(5):470-9. doi: 10.1097/01.cco.0000432523.24358.15.

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.
Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037.

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.
Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Mastronardi S, Boccomini C, Gaidano G, D’Arco AM, Di Raimondo F, Carella AM, Santoro A, Musto P, Federico M.
Ann Oncol. 2013 Aug;24(8):2108-12. doi: 10.1093/annonc/mdt137.

Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA.
Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009.

Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH.
Blood. 2013 May 30;121(22):4529-40. doi: 10.1182/blood-2012-12-471722.

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH.
Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063.

The primary mediastinal lymphoma: state of the art and therapeutical perspectives.
Foppoli M, Citterio G, Donadoni G, Govi S, Ferreri AJ.
Recenti Prog Med. 2013 May;104(5):203-8. doi: 10.1701/1291.14277.

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH.
Blood. 2013 Apr 4;121(14):2715-24. doi: 10.1182/blood-2012-10-461848.

Does consolidation radiotherapy provide a better disease control in patients with diffuse large B-cell lymphoma of Waldeyer’s ring?
Mian M, Ferreri AJ, Cortelazzo S; International Extranodal Lymphoma Study Group (IELSG).

Clin Oncol (R Coll Radiol). 2013 Apr;25(4):272-3. doi: 10.1016/j.clon.2012.11.012.

Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis.
Li ZM, Spagnuolo L, Mensah AA, Rinaldi A, Bhagat G, Zucca E, Doglioni C, Ferreri AJ, Ponzoni M, Bertoni F.
Br J Haematol. 2013 Mar;160(5):719-22. doi: 10.1111/bjh.12161.

Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A.
Crit Rev Oncol Hematol. 2013 Feb;85(2):216-37. doi: 10.1016/j.critrevonc.2012.07.002.

Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ, Govi S, Pileri SA, Savage KJ.
Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15. doi: 10.1016/j.critrevonc.2012.06.004.

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d’Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O’Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH.
Haematologica. 2013 Feb;98(2):255-63. doi: 10.3324/haematol.2012.066209.

Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice.
Copie-Bergman C, Wotherspoon AC, Capella C, Motta T, Pedrinis E, Pileri SA, Bertoni F, Conconi A, Zucca E, Ponzoni M, Ferreri AJ.
Br J Haematol. 2013 Jan;160(1):47-52. doi: 10.1111/bjh.12078.

Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer’s ring in remission after anthracycline-containing chemotherapy.
Mian M, Ferreri AJ, Rossi A, Conconi A, Tsang R, Gospodarowicz MK, Oldani E, Federico M, Luminari S, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Gutierrez-Garcia G, Busetto M, Cavalli F, Zucca E, Rambaldi A, Cortelazzo S; International Extranodal Lymphoma Study Group (Ielsg).
Leuk Lymphoma. 2013 Jan;54(1):62-8. doi: 10.3109/10428194.2012.710907.

A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma.
Ponzoni M, Govi S, Licata G, Mappa S, Giordano Resti A, Politi LS, Spagnuolo L, Di Cairano E, Doglioni C, Ferreri AJ.
Oncologist. 2013;18(7):876-84. doi: 10.1634/theoncologist.2012-0425.

Predictors of central nervous system involvement in diffuse large B-cell lymphoma: a divining rod is wanted.
Ferreri AJ.
Rev Bras Hematol Hemoter. 2013;35(4):235-6. doi: 10.5581/1516-8484.20130063.

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH.
Blood. 2012 Nov 8;120(19):3986-96. doi: 10.1182/blood-2012-05-433334.

Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?
Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarfò L, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T.
Am J Surg Pathol. 2012 Nov;36(11):1609-18. doi: 10.1097/PAS.0b013e318271243d.

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial.
Ferreri AJ, Govi S, Raderer M, Mulè A, Andriani A, Caracciolo D, Devizzi L, Ilariucci F, Luminari S, Viale E, Müllauer L, Dell’Oro S, Arcidiacono PG, Ponzoni M, Patti C.
Blood. 2012 Nov 1;120(18):3858-60. doi: 10.1182/blood-2012-06-438424.

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M.
J Clin Oncol. 2012 Nov 1;30(31):3848-53. doi: 10.1200/JCO.2010.33.4474.

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.
Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM; Fondazione Italiana Linfomi.
Blood. 2012 Oct 18;120(16):3222-8. doi: 10.1182/blood-2012-04-423095.

Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
Ferreri AJ, Bruno Ventre M, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M, Mappa S, Govi S, Di Nicola M, Rossi G, Tirelli U, Caligaris-Cappio F, Spina M, Re A.
Br J Haematol. 2012 Oct;159(2):252-5. doi: 10.1111/bjh.12020.

Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Joerger M, Huitema AD, Illerhaus G, Ferreri AJ.
Leuk Lymphoma. 2012 Oct;53(10):1867-75. doi: 10.3109/10428194.2012.676177.

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O’Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH.
Leukemia. 2012 Sep;26(9):2103-13. doi: 10.1038/leu.2012.83. Epub 2012 Mar 22. Erratum in: Leukemia. 2014 Apr;28(4):980.

Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.
Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R.
J Clin Oncol. 2012 Aug 20;30(24):2988-94. doi: 10.1200/JCO.2011.41.4466. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903.

Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ, Govi S, Pileri SA, Savage KJ.
Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302. doi: 10.1016/j.critrevonc.2012.02.005.

Hepatosplenic gamma-delta T-cell lymphoma.
Ferreri AJ, Govi S, Pileri SA.
Crit Rev Oncol Hematol. 2012 Aug;83(2):283-92. doi: 10.1016/j.critrevonc.2011.10.001.

Prevalence of chlamydial infection in a series of 108 primary cutaneous lymphomas.
Ferreri AJ, Ponzoni M, Govi S, Pasini E, Mappa S, Vino A, Facchetti F, Vezzoli P, Doglioni C, Berti E, Dolcetti R.
Br J Dermatol. 2012 May;166(5):1121-3. doi: 10.1111/j.1365-2133.2011.10704.x.

Mantle cell lymphoma.
Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M.
Crit Rev Oncol Hematol. 2012 Apr;82(1):78-101. doi: 10.1016/j.critrevonc.2011.05.001.

Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone.
Travi G, Ferreri AJ, Cinque P, Gerevini S, Ponzoni M, Terreni MR, Lazzarin A, Crippa F.
J Clin Oncol. 2012 Apr 1;30(10):e119-21. doi: 10.1200/JCO.2011.39.9642.

Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation.
Dagklis A, Ponzoni M, Govi S, Cangi MG, Pasini E, Charlotte F, Vino A, Doglioni C, Davì F, Lossos IS, Ntountas I, Papadaki T, Dolcetti R, Ferreri AJ, Stamatopoulos K, Ghia P.
Leukemia. 2012 Apr;26(4):814-21. doi: 10.1038/leu.2011.276. E

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.
Mian M, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner TC, Chan WC, Vose JM, Testoni M, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Uccella S, Tibiletti MG, Zucca E, Kwee I, Bertoni F.
Ann Oncol. 2012 Mar;23(3):729-35. doi: 10.1093/annonc/mdr289.

Primary CNS lymphoma.
Ferreri AJ, Marturano E.
Best Pract Res Clin Haematol. 2012 Mar;25(1):119-30. doi: 10.1016/j.beha.2011.12.001.

Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae.
Dolcetti R, Serraino D, Dognini G, Govi S, Crocchiolo R, Ghia P, Pasini E, Ponzoni M, Talamini R, De Paoli P, Doglioni C, Ferreri AJ.
Br J Cancer. 2012 Feb 28;106(5):966-9. doi: 10.1038/bjc.2012.2.

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.
Joerger M, Ferreri AJ, Krähenbühl S, Schellens JH, Cerny T, Zucca E, Huitema AD.
Br J Clin Pharmacol. 2012 Feb;73(2):240-7. doi: 10.1111/j.1365-2125.2011.04084.x.

Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U.
Oncologist. 2012;17(6):838-46. doi: 10.1634/theoncologist.2011-0417.

Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.
Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, DeAngelis LM.
Leukemia. 2011 Dec;25(12):1797-807. doi: 10.1038/leu.2011.169.

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, Chan WC, Chiappella A, Baldini L, Ferreri AJ, Gaidano G, Mian M, Zucca E, Bertoni F.
Br J Haematol. 2011 Oct;155(2):274-7. doi: 10.1111/j.1365-2141.2011.08675.x.

High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Joerger M, Huitema AD, Illerhaus G, Ferreri AJ.
Leuk Lymphoma. 2011 Oct;52(10):1825-7. doi: 10.3109/10428194.2011.580027.

Lymphoblastic lymphoma.
Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D.
Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. doi: 10.1016/j.critrevonc.2010.12.003. Epub 2011 Jan 26.

Peripheral T-cell lymphoma–not otherwise specified.
Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA.
Crit Rev Oncol Hematol. 2011 Sep;79(3):321-9. doi: 10.1016/j.critrevonc.2010.07.007.

How I treat primary CNS lymphoma.
Ferreri AJ.
Blood. 2011 Jul 21;118(3):510-22. doi: 10.1182/blood-2011-03-321349.

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.
J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187.

Enteropathy-associated T-cell lymphoma.
Ferreri AJ, Zinzani PL, Govi S, Pileri SA.
Crit Rev Oncol Hematol. 2011 Jul;79(1):84-90. doi: 10.1016/j.critrevonc.2010.06.006.

Genomic profiles of MALT lymphomas: variability across anatomical sites.
Kwee I, Rancoita PM, Rinaldi A, Ferreri AJ, Bhagat G, Gascoyne RD, Canzonieri V, Gaidano G, Doglioni C, Zucca E, Ponzoni M, Bertoni F.
Haematologica. 2011 Jul;96(7):1064-6. doi: 10.3324/haematol.2011.040402.

Integrated profiling of diffuse large B-cell lymphoma with 7q gain.
Chigrinova E, Mian M, Shen Y, Greiner TC, Chan WC, Vose JM, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Tucci A, Facchetti F, Lazure T, Lambotte O, Montes-Moreno S, Piris MA, Zucca E, Kwee I, Bertoni F.
Br J Haematol. 2011 May;153(4):499-503. doi: 10.1111/j.1365-2141.2011.08628.x.

Central nervous system marginal zone B-cell lymphoma associated with Chlamydophila psittaci infection.
Ponzoni M, Bonetti F, Poliani PL, Vermi W, Bottelli C, Dolcetti R, Cangi MG, Ferreri AJ, Cin ED, Pasini E, Liserre R, Doglioni C, Rossi G, Facchetti F.
Hum Pathol. 2011 May;42(5):738-42. doi: 10.1016/j.humpath.2010.08.014.

Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
Ferreri AJ, Verona C, Politi LS, Chiara A, Perna L, Villa E, Reni M.
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):169-75. doi: 10.1016/j.ijrobp.2010.01.066.

CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11).
Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S.
Ann Hematol. 2011 Apr;90(4):401-8. doi: 10.1007/s00277-010-1083-1.

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG).
Ann Oncol. 2011 Mar;22(3):689-95. doi: 10.1093/annonc/mdq416.

Activity of clarithromycin in mucosa-associated lymphoid tissue-type lymphomas: antiproliferative drug or simple antibiotic?
Ferreri AJM.
Chest. 2011 Mar;139(3):724-725. doi: 10.1378/chest.10-2454.

Gastric lymphoma: the histology report.
Doglioni C, Ponzoni M, Ferreri AJ, Savio A; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP).
Dig Liver Dis. 2011 Mar;43 Suppl 4:S310-8. doi: 10.1016/S1590-8658(11)60587-2.

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.
Chigrinova E, Mian M, Scandurra M, Greiner TC, Chan WC, Vose JM, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Tucci A, Facchetti F, Lazure T, Lambotte O, Montes-Moreno S, Piris MA, Nomdedeu JF, Uccella S, Rancoita PM, Kwee I, Zucca E, Bertoni F.
Hematol Oncol. 2011 Mar;29(1):38-41. doi: 10.1002/hon.953.

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.
Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, Rancoita PM, De Campos CP, Forconi F, Gascoyne RD, Facchetti F, Ponzoni M, Govi S, Ferreri AJ, Mollejo M, Piris MA, Baldini L, Soulier J, Thieblemont C, Canzonieri V, Gattei V, Marasca R, Franceschetti S, Gaidano G, Tucci A, Uccella S, Tibiletti MG, Dirnhofer S, Tripodo C, Doglioni C, Dalla Favera R, Cavalli F, Zucca E, Kwee I, Bertoni F.
Blood. 2011 Feb 3;117(5):1595-604. doi: 10.1182/blood-2010-01-264275.

Whole-brain radiotherapy in primary CNS lymphoma.
Ferreri AJ, DeAngelis L, Illerhaus G, O’Neill BP, Reni M, Soussain C, Yahalom J.
Lancet Oncol. 2011 Feb;12(2):118-9; author reply 119-20. doi: 10.1016/S1470-2045(11)70018-3.

Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas.
Ponzoni M, Ferreri AJ, Mappa S, Pasini E, Govi S, Facchetti F, Fanoni D, Tucci A, Vino A, Doglioni C, Berti E, Dolcetti R.
Oncologist. 2011;16(11):1582-8. doi: 10.1634/theoncologist.2011-0108.

Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M.
Oncologist. 2011;16(3):336-41. doi: 10.1634/theoncologist.2010-0361.

Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G.
Ophthalmology. 2011 Jan;118(1):24-8. doi: 10.1016/j.ophtha.2010.04.036.

Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells.
Venetz D, Ponzoni M, Schiraldi M, Ferreri AJ, Bertoni F, Doglioni C, Uguccioni M.
Int J Cancer. 2010 Nov 15;127(10):2300-12. doi: 10.1002/ijc.25236.

Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, Pruneri G, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F.
Br J Haematol. 2010 Nov;151(3):221-31. doi: 10.1111/j.1365-2141.2010.08326.x.

Treatment of primary central nervous system lymphoma: recent advances.
Foppoli M, Ferreri AJ.
Recenti Prog Med. 2010 Oct;101(10):376-80. Italian.

Intravascular lymphoma occurring in patients with other non-Hodgkin lymphomas.
Ponzoni M, Campo E, Ferreri AJ.
Clin Adv Hematol Oncol. 2010 Sep;8(9):641-2.

Unconventional therapies in ocular adnexal lymphomas.
Ponzoni M, Ferreri AJ, Doglioni C, Dolcetti R.
Expert Rev Anticancer Ther. 2010 Sep;10(9):1341-3. doi: 10.1586/era.10.125.

Flows and flaws in primary central nervous system lymphoma.
Ferreri AJ, Illerhaus G, Zucca E, Cavalli F; International Extranodal Lymphoma Study Group.

Nat Rev Clin Oncol. 2010 Aug;7(8):doi:10.1038/nrclinonc.2010.9-c1; author reply doi:10:1038/nrclinonc.2010.9-c2. doi: 10.1038/nrclinonc.2010.9-c1.

Ocular adnexal lymphoma: diffusion-weighted mr imaging for differential diagnosis and therapeutic monitoring.
Politi LS, Forghani R, Godi C, Resti AG, Ponzoni M, Bianchi S, Iadanza A, Ambrosi A, Falini A, Ferreri AJ, Curtin HD, Scotti G.
Radiology. 2010 Aug;256(2):565-74. doi: 10.1148/radiol.10100086.

Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.
Govi S, Dognini GP, Licata G, Crocchiolo R, Resti AG, Ponzoni M, Ferreri AJ.
Br J Haematol. 2010 Jul;150(2):226-9. doi: 10.1111/j.1365-2141.2010.08179.x.

Treatment approaches for primary CNS lymphomas.
Carrabba MG, Reni M, Foppoli M, Chiara A, Franzin A, Politi LS, Villa E, Ciceri F, Ferreri AJ.
Expert Opin Pharmacother. 2010 Jun;11(8):1263-76. doi: 10.1517/14656561003767456.

Consolidation radiotherapy for a rare case of extranodal mucosa-associated lymphoid tissue non-Hodgkin’s lymphoma synchronous with prostate adenocarcinoma.
Alongi F, Aniko MD, Ferreri AJ, Rosso A, Cozzarini C, Fallanca F, Berardi G, Schipani S, Gianolli L, Guazzoni G, Di Muzio N.
Tumori. 2010 May-Jun;96(3):498-502.

Genetic and epigenetic changes linked to Chlamydophila psittaci-associated ocular adnexal lymphomas.
Dolcetti R, Ponzoni M, Ferreri AJ, Doglioni C.
Hematol Oncol. 2010 Mar;28(1):1-2. doi: 10.1002/hon.934.

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri AJ.
Br J Cancer. 2010 Feb 16;102(4):673-7. doi: 10.1038/sj.bjc.6605559.

Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma.
Crocchiolo R, Fallanca F, Giovacchini G, Ferreri AJ, Assanelli A, Verona C, Pescarollo A, Bregni M, Ponzoni M, Gianolli L, Fazio F, Ciceri F.
Ann Hematol. 2009 Dec;88(12):1229-36. doi: 10.1007/s00277-009-0752-4.

Chlamydial infection: the link with ocular adnexal lymphomas.
Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Ponzoni M.
Nat Rev Clin Oncol. 2009 Nov;6(11):658-69. doi: 10.1038/nrclinonc.2009.147. Epub 2009 Oct 6. Review. Erratum in: Nat Rev Clin Oncol. 2009 Dec;6(12):678.

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG).
Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1.

Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here?
Ponzoni M, Dolcetti R, Doglioni C, Ferreri AJ.
Blood. 2009 Oct 15;114(16):3499; author reply 3499-500. doi: 10.1182/blood-2009-07-234021.

Primary intracranial meningeal marginal zone B cell lymphoma of malt type (PMML) with osseous infiltration.
Famoso G, Ponzoni M, Terreni MR, Assanelli A, Mortini P, Doglioni C, Ferreri AJ.
Ann Hematol. 2009 Jun;88(6):599-601. doi: 10.1007/s00277-008-0638-x.

Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F.
Hematol Oncol. 2009 Jun;27(2):61-70. doi: 10.1002/hon.881.

BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri AJ, Pinotti G, Assanelli A, Scandurra M, Doglioni C, Zucca E, Capella C, Bertoni F.
Hum Pathol. 2009 May;40(5):645-52. doi: 10.1016/j.humpath.2008.06.032.

Infectious agents and lymphoma development: molecular and clinical aspects.
Ferreri AJ, Ernberg I, Copie-Bergman C.
J Intern Med. 2009 Apr;265(4):421-38. doi: 10.1111/j.1365-2796.2009.02083.x.

Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial.
Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E.
Br J Haematol. 2009 Feb;144(3):367-75. doi: 10.1111/j.1365-2141.2008.07486.x.

Primary mediastinal large B-cell lymphoma.
Martelli M, Ferreri AJ, Johnson P.
Crit Rev Oncol Hematol. 2008 Dec;68(3):256-63. doi: 10.1016/j.critrevonc.2008.07.020.

Angioimmunoblastic T-cell lymphoma.
Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH.
Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71. doi: 10.1016/j.critrevonc.2008.06.012.

Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D’Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M.
J Clin Oncol. 2008 Nov 1;26(31):5134-6; author reply 5136-7. doi: 10.1200/JCO.2008.19.1841.

High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions.
Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M.
Leuk Lymphoma. 2008 Nov;49(11):2042-7. doi: 10.1080/10428190802381238.

Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE.

The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma.
Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalbán C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, Ponzoni M; International Extranodal Lymphoma Study Group.
Br J Haematol. 2008 Oct;143(2):253-7. doi: 10.1111/j.1365-2141.2008.07338.x.

The impact of histopathologic diagnosis on the proper management of testis neoplasms.
Ponti G, Ponzoni M, Ferreri AJ, Foppoli M, Mazzucchelli L, Zucca E.
Nat Clin Pract Oncol. 2008 Oct;5(10):619-22. doi: 10.1038/ncponc1218.

Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods.
Ponzoni M, Ferreri AJ, Guidoboni M, Lettini AA, Cangi MG, Pasini E, Sacchi L, Pecciarini L, Grassi S, Dal Cin E, Stefano R, Magnino S, Dolcetti R, Doglioni C.
Clin Cancer Res. 2008 Sep 15;14(18):5794-800. doi: 10.1158/1078-0432.CCR-08-0676.

Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?
Decaudin D, Dolcetti R, de Cremoux P, Ponzoni M, Vincent-Salomon A, Doglioni C, Dendale R, Escande MC, Lumbroso-Le Rouic L, Ferreri AJ.
Anticancer Drugs. 2008 Sep;19(8):761-5. doi: 10.1097/CAD.0b013e32830b58c4.

CNS Hodgkin lymphoma.
Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT.
Blood. 2008 Sep 1;112(5):1658-61. doi: 10.1182/blood-2008-04-151563.

Practice guidelines for the management of extranodal non-Hodgkin’s lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Zinzani PL, Martelli M, Poletti V, Vitolo U, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.
Haematologica. 2008 Sep;93(9):1364-71. doi: 10.3324/haematol.12742.

Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study.
Ferreri AJ, Dolcetti R, Dognini GP, Malabarba L, Vicari N, Pasini E, Ponzoni M, Cangi MG, Pecciarini L, Resti AG, Doglioni C, Rossini S, Magnino S.
Int J Cancer. 2008 Sep 1;123(5):1089-93. doi: 10.1002/ijc.23596.

Lymphoplasmacytic lymphoma-Waldenstrom’s macroglobulinemia.
Vitolo U, Ferreri AJ, Montoto S.
Crit Rev Oncol Hematol. 2008 Aug;67(2):172-85. doi: 10.1016/j.critrevonc.2008.03.008.

Successful pregnancy after chemo-immuno-radiation therapy for aggressive lymphoma of the uterus.
Ferreri AJ, Verona C, Bolognesi A, Taccagni G, Ponzoni M, Ferrari S.
Br J Haematol. 2008 Jul;142(1):141-3. doi: 10.1111/j.1365-2141.2008.07083.x.

Follicular lymphomas.
Vitolo U, Ferreri AJ, Montoto S.
Crit Rev Oncol Hematol. 2008 Jun;66(3):248-61. doi: 10.1016/j.critrevonc.2008.01.014.

Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy.
Ferreri AJ, Dolcetti R, Du MQ, Doglioni C, Resti AG, Politi LS, De Conciliis C, Radford J, Bertoni F, Zucca E, Cavalli F, Ponzoni M.
Ann Oncol. 2008 May;19(5):835-46.

Primary testicular lymphoma.
Vitolo U, Ferreri AJ, Zucca E.
Crit Rev Oncol Hematol. 2008 Feb;65(2):183-9.

Mycosis fungoides.
Zinzani PL, Ferreri AJ, Cerroni L.
Crit Rev Oncol Hematol. 2008 Feb;65(2):172-82.

Chlamydia-psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma.
Ferreri AJ, Dognini GP, Ponzoni M, Pecciarini L, Cangi MG, Santambrogio G, Resti AG, De Conciliis C, Magnino S, Pasini E, Vicari N, Dolcetti R, Doglioni C.
Ann Oncol. 2008 Jan;19(1):194-5.

Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.
Rubenstein J, Ferreri AJ, Pittaluga S.
Leuk Lymphoma. 2008;49 Suppl 1:43-51. doi: 10.1080/10428190802311441.

Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Reni M, Mazza E, Foppoli M, Ferreri AJ.
Cancer Lett. 2007 Dec 18;258(2):165-70.

Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE.
Ann Oncol. 2007 Nov;18(11):1851-5.

Primary CNS lymphomas prognosis.
Ferreri AJ, Reni M, Zucca E, Cavalli F.
J Clin Oncol. 2007 Sep 20;25(27):4322-4; author reply 4324-5.

A woman and her canary: a tale of chlamydiae and lymphomas.
Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Cangi MG, Pecciarini L, Ghia P, Dagklis A, Pasini E, Vicari N, Dognini GP, Resti AG, Ponzoni M.
J Natl Cancer Inst. 2007 Sep 19;99(18):1418-9.

Primary central nervous system lymphoma.
Ferreri AJ, Reni M.
Crit Rev Oncol Hematol. 2007 Sep;63(3):257-68.

Marginal-zone lymphoma.
Ferreri AJ, Zucca E.
Crit Rev Oncol Hematol. 2007 Sep;63(3):245-56.

Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas.
Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJ, Dell’Oro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, Iuzzolino P, Motta T, Carbone A, Pedrinis E, Sanchez J, Blay JY, Reni M, Conconi A, Bertoni F, Zucca E, Cavalli F, Borisch B; International Extranodal Lymphoma Study Group.
Br J Haematol. 2007 Aug;138(3):316-23.

Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.
Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S.
J Clin Oncol. 2007 Jul 20;25(21):3168-73.

Primary diffuse large B-cell lymphoma of the stomach.
Ferreri AJ, Montalbán C.
Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71.

Therapeutic management of ocular adnexal MALT lymphoma.
Ferreri AJ, Assanelli A, Crocchiolo R, Dognini GP, Resti AG, Politi LS, Doglioni C, Cappio FC, Dolcetti R, Ponzoni M.
Expert Opin Pharmacother. 2007 Jun;8(8):1073-83.

Primary central nervous system lymphoma: biological aspects and controversies in management.
Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M.
Eur J Cancer. 2007 May;43(7):1141-52.

Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.
Ferreri AJ, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalbán C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A, Pertoldi B, Horváth B, Szomor A, Zucca E, Cavalli F, Ponzoni M; International Extranodal Lymphoma Study Group (IELSG).
Haematologica. 2007 Apr;92(4):486-92.

Temozolomide as salvage treatment in primary brain lymphomas.
Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ.
Br J Cancer. 2007 Mar 26;96(6):864-7.

Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, Ponzoni M.
Haematologica. 2007 Jan;92(1):e1-2.

A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals.
Ponzoni M, Kwee I, Mazzucchelli L, Ferreri AJ, Zucca E, Doglioni C, Cavalli F, Bertoni F.
Pathobiology. 2007;74(4):264-9.

Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial.
Ferreri AJ, Ponzoni M, Dognini GP, Du MQ, Doglioni C, Radford J, Dolcetti R, Cavalli F.
Ann Oncol. 2006 Nov;17(11):1721-2.

Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R.
J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82.

Intravascular lymphoma: a neoplasm of ‘homeless’ lymphocytes?
Ponzoni M, Ferreri AJ.
Hematol Oncol. 2006 Sep;24(3):105-12.

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Ferreri AJ, Dell’Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M.
Neurology. 2006 May 9;66(9):1435-8.

Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa.
Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, Lettini AA, Sacchetti F, Dolcetti R, Doglioni C, Ponzoni M.
Ann Oncol. 2006 May;17(5):769-72.

The prevalence and clinical implications of c-kit expression in plasma cell myeloma.
Pruneri G, Ponzoni M, Ferreri AJ, Freschi M, Tresoldi M, Baldini L, Mattioli M, Agnelli L, Govi S, Mancuso P, Agazzi A, Bertolini F, Peccatori J, Bosari S, Gianelli U, Viale G, Neri A.
Histopathology. 2006 Apr;48(5):529-35.

Hematologic malignancies: from clinical science to clinical practice – 2nd European Congress.
Ferreri AJ.
IDrugs. 2006 Apr;9(4):242-6.

Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin’s lymphomas.
Tirelli U, Balzarotti M, Uziel L, Ferreri AJ, Santoro A, Spina M.
Ann Oncol. 2006 Mar;17(3):533.

Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications.
Ferreri AJ, Ponzoni M, Viale E, Guidoboni M, Conciliis CD, Resti AG, Politi L, Lettini AA, Sacchetti F, Dognini G, Dolcetti R, Doglioni C.
Hematol Oncol. 2006 Mar;24(1):33-7.

Re: Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.
de Cremoux P, Subtil A, Ferreri AJ, Vincent-Salomon A, Ponzoni M, Chaoui D, Arnaud P, Lumbroso-Le Rouic L, Sacchetti F, Dendale R, Thioux M, Escande MC, Stern MH, Dolcetti R, Decaudin D.
J Natl Cancer Inst. 2006 Mar 1;98(5):365-6.

Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives.
Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R.
Clin Lymphoma Myeloma. 2006 Jan;6(4):289-300.

Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.
Ferreri AJ, Ponzoni M, Martinelli G, Muti G, Guidoboni M, Dolcetti R, Doglioni C.
Haematologica. 2005 Nov;90(11):1578-9.

Prognostic factors in primary central nervous system lymphomas.
Ferreri AJ, Reni M.
Hematol Oncol Clin North Am. 2005 Aug;19(4):629-49.

Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy.
Ferreri AJ, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Mazzi B, Lettini AA, Demeter J, Dell’Oro S, Doglioni C, Villa E, Boiocchi M, Dolcetti R.
J Clin Oncol. 2005 Aug 1;23(22):5067-73.

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F; International Primary CNS Lymphoma Collaborative Group.
J Clin Oncol. 2005 Aug 1;23(22):5034-43.

Target delineation in post-operative radiotherapy of brain gliomas: interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans.
Cattaneo GM, Reni M, Rizzo G, Castellone P, Ceresoli GL, Cozzarini C, Ferreri AJ, Passoni P, Calandrino R.
Radiother Oncol. 2005 May;75(2):217-23.

Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
Shenkier TN, Blay JY, O’Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O’Brien P, Rubenstein J, Connors JM.
J Clin Oncol. 2005 Apr 1;23(10):2233-9.

Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E.
J Clin Oncol. 2005 Mar 20;23(9):1979-83.

Establishing a prognostic score for primary CNS lymphomas.
Ferreri AJ, Reni M.
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):303-4; author reply 304-5.

Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining.
Ponzoni M, Savage DG, Ferreri AJ, Pruneri G, Viale G, Servida P, Bertolini F, Orazi A.
Mod Pathol. 2004 Dec;17(12):1513-20.

No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients.
Martini F, Dolcetti R, Ferreri AJ, Ponzoni M, Fumagalli L, Reni M, Terreni MR, Mariuzzi L, Tognon M.
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1819-20.

Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’.
Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, López-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M; International Extranodal Lymphoma Study Group (IELSG).
Br J Haematol. 2004 Oct;127(2):173-83.

Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ, Dell’Oro S, Capello D, Ponzoni M, Iuzzolino P, Rossi D, Pasini F, Ambrosetti A, Orvieto E, Ferrarese F, Arrigoni G, Foppoli M, Reni M, Gaidano G.
Br J Haematol. 2004 Sep;126(5):657-64.

Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.
Ferreri AJ, Campo E, Ambrosetti A, Ilariucci F, Seymour JF, Willemze R, Arrigoni G, Rossi G, López-Guillermo A, Berti E, Eriksson M, Federico M, Cortelazzo S, Govi S, Frungillo N, Dell’Oro S, Lestani M, Asioli S, Pedrinis E, Ungari M, Motta T, Rossi R, Artusi T, Iuzzolino P, Zucca E, Cavalli F, Ponzoni M.
Ann Oncol. 2004 Aug;15(8):1215-21.

Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.
Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell’Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ.
Eur J Cancer. 2004 Jul;40(11):1682-8.

Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients.
Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, Zannini P, Traversari C.
Oncol Rep. 2004 Jul;12(1):145-51.

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M; Gruppo Italiano Cooperativo di Neuro-Oncologia.
J Clin Oncol. 2004 May 1;22(9):1598-604.

Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.
Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell’Oro S, Fleischhauer K, Caggiari L, Lettini AA, Dal Cin E, Ieri R, Freschi M, Villa E, Boiocchi M, Dolcetti R.
J Natl Cancer Inst. 2004 Apr 21;96(8):586-94.

Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?
Reni M, Ferreri AJ.
J Clin Oncol. 2004 Mar 15;22(6):1165-7; authir reply 1167-8.

Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell’Oro S, Locatelli M, Villa E, Reni M.
Br J Cancer. 2004 Jan 26;90(2):353-8.

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell’Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E.
Blood. 2003 Oct 15;102(8):2741-5.

Current therapeutic approaches to primary CNS lymphoma.
Ferreri AJ, Dell’Oro S, Reni M.
Expert Rev Neurother. 2003 Sep;3(5):673-83. doi: 10.1586/14737175.3.5.673.

Questions and answers in the management of primary central nervous system and ocular lymphomas.
Ferreri AJ, Dell’oro S, Reni M, Foppoli M, Anzalone N, Govi S, Picozzi P, Truci G, Ponzoni M.
Haematologica. 2003 Sep;88(9):1063-8.

Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome.
Ponzoni M, Ferreri AJ, Pruneri G, Pozzi B, Dell’Oro S, Pigni A, Pinotti G, Villa E, Freschi M, Viale G, Capella C.
Int J Cancer. 2003 Aug 20;106(2):288-91.

Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation.
Pruneri G, Fabris S, Fasani R, Del Curto B, Capella C, Pozzi B, Motta T, Andreola S, Ferreri AJ, Ponzoni M, Viale G, Neri A.
J Pathol. 2003 Aug;200(5):596-601.

Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.
Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T.
J Clin Oncol. 2003 Jun 15;21(12):2407-14.

International Collaborative Group against Primary CNS Lymphomas.
Ferreri AJ, Batchelor T, Zucca E, Cavalli F, Armitage J.
J Clin Oncol. 2003 Apr 15;21(8):1649-50.

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F; International Extranodal Lymphoma Study Group.
Blood. 2003 Apr 1;101(7):2489-95.

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F.
J Clin Oncol. 2003 Jan 15;21(2):266-72.

Guidelines for the treatment of primary central nervous system lymphomas in immunocompetent patients.
Ferreri AJ, Dell Oro S, Reni M.
Forum (Genova). 2003;13(1):33-45.

Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.
Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK; International Extranodal Lymphoma Study Group.
J Clin Oncol. 2003 Jan 1;21(1):20-7.

Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.
Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG).
Haematologica. 2002 Dec;87(12):1258-64.

Primary brain CD30+ ALK1+ anaplastic large cell lymphoma (‘ALKoma’): the first case with a combination of ‘not common’ variants.
Ponzoni M, Terreni MR, Ciceri F, Ferreri AJ, Gerevini S, Anzalone N, Valle M, Pizzolito S, Arrigoni G.
Ann Oncol. 2002 Nov;13(11):1827-32.

Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren’s syndrome and gastric MALT lymphoma.
Folli F, Perego L, Ponzoni M, Girardi AM, Bosi E, Ferreri AJ, Bellone M, Sabbadini MG, Vicari AM, Trusolino L.
Ann Hematol. 2002 Oct;81(10):597-602.

Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients.
Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F, Viale G.
Br J Haematol. 2002 Sep;118(3):817-20.

The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies.
Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L, Gianni AM, Cavalli F, Barbui T; International Extranodal Lymphoma Study Group (IELSG).
Br J Haematol. 2002 Jul;118(1):218-28.

A multicenter study of treatment of primary CNS lymphoma.
Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F, Blay JY.
Neurology. 2002 May 28;58(10):1513-20.

Relevance of intraocular involvement in the management of primary central nervous system lymphomas.
Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M, Cavalli F; International Extranodal Lymphoma Study Group (IELSG).
Ann Oncol. 2002 Apr;13(4):531-8.

Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation.
Della Volpe A, Ferreri AJ, Annaloro C, Mangili P, Rosso A, Calandrino R, Villa E, Lambertenghi-Deliliers G, Fiorino C.
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):483-8.

Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin’s lymphoma.
Ferreri AJ, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell’Oro S, Baldini L, Buffa R, Carboni N, Villa E, Viale G.
Int J Cancer. 2001 Nov;94(4):599-604.

Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E.
Lung Cancer. 2001 Nov;34(2):279-87.

Therapeutic management of primary CNS lymphoma in immunocompetent patients.
Reni M, Ferreri AJ.
Expert Rev Anticancer Ther. 2001 Oct;1(3):382-94.

Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate.
Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell’Oro S, Biron P, Hochberg FH.
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):419-25.

Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma.
Reni M, Panucci MG, Ferreri AJ, Balzano G, Passoni P, Cattaneo GM, Cordio S, Scaglietti U, Zerbi A, Ceresoli GL, Fiorino C, Calandrino R, Staudacher C, Villa E, Di Carlo V.
Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8.

Irradiation fields and doses in glioblastoma multiforme: are current standards adequate?
Reni M, Cozzarini C, Panucci MG, Ceresoli GL, Ferreri AJ, Fiorino C, Truci G, Falini A, Tartara F, Terreni MR, Verusio C, Villa E.
Tumori. 2001 Mar-Apr;87(2):85-90.

Prognostic significance of the histopathologic recognition of low- and high-grade components in stage I-II B-cell gastric lymphomas.
Ferreri AJ, Freschi M, Dell’Oro S, Viale E, Villa E, Ponzoni M.
Am J Surg Pathol. 2001 Jan;25(1):95-102.

Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M, Ferreri AJ.
Ann Hematol. 2001;80 Suppl 3:B113-7.

Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ, Reni M, Dell’Oro S, Ciceri F, Bernardi M, Camba L, Ponzoni M, Terreni MR, Tomirotti M, Spina M, Villa E.
Oncology. 2001;60(2):134-40.

Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Ferreri AJ, Reni M, Villa E.
Ann Oncol. 2000 Aug;11(8):927-37.

Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Reni M, Ferreri AJ, Landoni C, Villa E.
J Natl Cancer Inst. 2000 Apr 5;92(7):575-6.

Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas.
Ferreri AJ, Dell’Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E.
Oncology. 2000 Apr;58(3):219-26.

A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme.
Reni M, Cozzarini C, Ferreri AJ, Ceresoli GL, Galli L, Bianchi A, Villa E.
Cancer Invest. 2000;18(6):510-5.

Diffuse large-cell lymphoma of the testis.
Tondini C, Ferreri AJ, Siracusano L, Valagussa P, Giardini R, Rampinelli I, Bonadonna G.
J Clin Oncol. 1999 Sep;17(9):2854-8.

Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma.
Ferreri AJ, Cordio S, Ponzoni M, Villa E.
Leuk Lymphoma. 1999 May;33(5-6):531-41.

Second-line treatment for primary central nervous system lymphoma.
Reni M, Ferreri AJ, Villa E.
Br J Cancer. 1999 Feb;79(3-4):530-4.

Therapeutic management of stage I-II high-grade primary gastric lymphomas.
Ferreri AJ, Cordio S, Paro S, Ponzoni M, Freschi M, Veglia F, Villa E.
Oncology. 1999;56(4):274-82.

Low sensitivity of computed tomography in the staging of gastric lymphomas of mucosa-associated lymphoid tissue: impact on prospective trials and ordinary clinical practice.
Ferreri AJ, Ponzoni M, Cordio S, Vanzulli A, Garuti E, Viale E, Villa E.
Am J Clin Oncol. 1998 Dec;21(6):614-6.

Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases.
Ceresoli GL, Ferreri AJ, Cordio S, Villa E.
Oncology. 1998 Nov-Dec;55(6):525-32.

Therapeutic management with adriamycin-containing chemotherapy and radiotherapy of monostotic and polyostotic primary non-Hodgkin’s lymphoma of bone in adults.
Ferreri AJ, Reni M, Ceresoli GL, Villa E.
Cancer Invest. 1998;16(8):554-61.

Primary cardiac lymphoma in immunocompetent patients: diagnostic and therapeutic management.
Ceresoli GL, Ferreri AJ, Bucci E, Ripa C, Ponzoni M, Villa E.
Cancer. 1997 Oct 15;80(8):1497-506.

Primary brain lymphomas in patients with a prior or concomitant malignancy.
Reni M, Ferreri AJ, Zoldan MC, Villa E.
J Neurooncol. 1997 Apr;32(2):135-42.

Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.
Reni M, Ferreri AJ, Garancini MP, Villa E.
Ann Oncol. 1997 Mar;8(3):227-34.

Importance of complete staging in non-Hodgkin’s lymphoma presenting as a cerebral mass lesion.
Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E.
Cancer. 1996 Mar 1;77(5):827-33.

Combined therapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ, Reni M, Bolognesi A, Verusio C, Villa E.
Eur J Cancer. 1995 Nov;31A(12):2008-12.

Preclinical evaluation of the ribosome-inactivating proteins PAP-1, PAP-S and RTA in mice.
Benigni F, Canevari S, Gadina M, Adobati E, Ferreri AJ, Di Celle EF, Comolli R, Colnaghi MI.
Int J Immunopharmacol. 1995 Oct;17(10):829-39.

Primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ, Reni M, Villa E.
Cancer Treat Rev. 1995 Sep;21(5):415-46.

Microsurgical anatomy of arteries related to the internal acoustic meatus.
Brunsteins DB, Ferreri AJ.
Acta Anat (Basel). 1995;152(2):143-50.

[The corrosion casting technique for the study of the temporal bone and its contents].
Ferreri AJ, Mansi HD, Castanon JA, Teragni E.
Bull Assoc Anat (Nancy). 1994 Sep;78(242):9-13. French.

Combined modality treatment for primary gastrointestinal non-Hodgkin’s lymphoma: the Milan Cancer Institute experience.
Tondini C, Giardini R, Bozzetti F, Valagussa P, Santoro A, Bertulli R, Balzarotti M, Rocca A, Lombardi F, Ferreri AJ, et al.
Ann Oncol. 1993 Dec;4(10):831-7.

Production and characterization of a monoclonal antibody against the ribosome inactivating protein alpha sarcin.
Ferreri AJ, Ferraris di Celle E, Caldera M, Muñoz S, Salvarelli S, Conde F, Canevari S, Tosi E, Colnaghi MI.
Hybridoma. 1992 Aug;11(4):437-46.

Relationship between the development of diaphragma sellae and the morphology of the sella turcica and its content.
Ferreri AJ, Garrido SA, Markarian MG, Yañez A.
Surg Radiol Anat. 1992;14(3):233-9.

Microsurgical anatomy of VII and VIII cranial nerves and related arteries in the cerebellopontine angle.
Brunsteins DB, Ferreri AJ.
Surg Radiol Anat. 1990;12(4):259-65.

Books

– “Mastología dinámica”
Alvarez Gardiol E, Tejerina Gomez A
Ediciones Diaz de Santos S.A:, Madrid, España, 1994.
Autore del capitolo 43 “Principios, resultados y prospectiva de la cirugía conservadora” (Testo in spagnolo)
Veronesi U, Farante G, Sacchini V, Ferreri AJM

– “Controversias en cáncer de mama”
Veronesi U e 30 coautori
Collana della European School of Oncology “Avances en Oncología” Artes Gráficas Aconcagua S.A, Buenos Aires, Argentina, 1996. Coordinatore scientifico (Testo in spagnolo)

– “Avances en mastología”
Hernandez Muñoz GA
Seconda edizione, Caracas, Venezuela, 1996.
Autore del capitolo (Testo in spagnolo)
“Quimioprevención del cáncer de mama con tamoxifeno”
Farante G, Costa A, Sacchini V, Ferreri AJM, Bonami B, De Censi A

– “Le infezioni erpetiche nel paziente immunocompromesso” Ferreri AJM, Reni M
Pharma Project Group Edizioni Scientifiche, Saronno, Italia, 1996 Autore del libro (Testo in italiano)

– “Non Hodgkin’s lymphomas”
State of the Art, Oncology in Europe http://www.cancerworld.org Editore associato (Testo in inglese)

– “Hodgkin’s disease”
State of the Art, Oncology in Europe, Editore associato (Testo in inglese)

– Clinical Hematology
N. Young, S. Gerson & K. High. Autore del capitolo 42: Primary and secondary central nervous system lymphomas in immunocompetent and HIV-positive patients (Testo in inglese)
Abrey L. & Ferreri AJM

– Lymphoma: Pathology, Diagnosis and Treatment
R. Marcus, J. W. Seetenham, M. E. Williams
Cambridge University Press, 2007. Autore del capitolo 14: Central nervous system lymphoma (Testo in inglese) Ferreri AJM & DeAngelis LM.

– Research Advances in Neurology
GRN Press, 2007
Autore del capitolo: New therapeutic approaches for primary CNS lymphomas (Testo in inglese)
Ferreri AJM, Crocchiolo R, Dognini GP, et al.

– Extranodal Lymphomas: Pathology and Management
F. Cavalli, H. Stein & E. Zucca
Informa Healthcare, 2008
Autore del capitolo 11: Primary Central nervous system lymphoma (Testo in inglese) Batchelor TT & Ferreri AJM.

– Extranodal Lymphomas: Pathology and Management
F. Cavalli, H. Stein & E. Zucca
Informa Healthcare, 2008
Autore del capitolo 13: Intravascular large B-cell lymphoma (Testo in inglese) Ponzoni M, Murase T, Ferreri AJM &, S. Nakamura.

– Extranodal Lymphomas: Pathology and Management
F. Cavalli, H. Stein & E. Zucca
Informa Healthcare, 2008
Autore del capitolo 19: MALT-type lymphoma of the orbit and ocular adnexae (Testo in inglese) Ferreri AJM, Radford J, Doglioni C, & Ponzoni M.

– Eye cancer research progress
Edwin E. Bospene
Nova Science Publisher, 2008
Autore del capitolo: Ocular adnexal MALT lymphoma: biology, diagnosis and treatment (Testo in inglese) Ferreri AJM, Dognini GP, Giordano resti A, Politi LS, Licata G, Cangi MG, Pecciarini L, Doglioni C, & Ponzoni M.

– Medicina interna sistematica
Claudio Rugarli
Elsevier, 6a edizione, 2010
Autore del capitolo: Disordini linfoproliferativi (Testo in italiano) Ferreri AJM, Ghia P, Govi S, & Ponzoni M.

– Medicina interna sistematica
Claudio Rugarli
Elsevier, 6a edizione, 2010
Autore del capitolo: Disordini plasmacellulari (Testo in italiano) Ferreri AJM & Ghia P.

– Bacteria and cancer
A. A. Khan
Springer Science+Business Media, 1st edition, 2012. Autore del capitolo 6: Ocular adnexal lymphoma of MALT-type and its association with Chlamydophila psittaci infection (Testo in inglese)
Ferreri AJM, Dolcetti R, Govi S, & Ghia P.

– Autoimmune Disorders – Pathogenetic Aspects
Clio P. Mavragani
InTech, DOI: 10.5772/802. Autore del capitolo 19: Autoimmune disorders and lymphomas (Testo in inglese) Dolcetti R, Ponzoni M, Mappa S, & Ferreri AJM.

– Lymphomas – Esentials for clinicians
Michele Ghielmini & Silvia Montoto
ESMO Press, ISBN: 978-88-906359-2-2. Autore del capitolo 14: History of lymphoma classification (Testo in inglese) Ponzoni M & Ferreri AJM.

– Lymphomas – Esentials for clinicians
Michele Ghielmini & Silvia Montoto
ESMO Press, ISBN: 978-88-906359-2-2. Autore del capitolo 22: Extranodal lymphomas (Testo in inglese) Ferreri AJM & Ponzoni M.

Attività Editoriale

Coordinatore della Segretaria di Redazione della Rivista Latinoamericana della European School of Oncology: “Nuevas Tendencias en Oncologia"

Coordinatore Editoriale della Rivista Latinoamericana di Mastologia della European School of Oncology: “Revista Latinoamericana de Mastología"

Editore Associato al Progetto ESO / START per i 16 capitoli riguardanti “Non-Hodgkin’s lymphomas" e “Hodgkin’s disease" (versioni in inglese e italiano).

Editore Associato di “Hematological Oncology" dal 2008 ad oggi.

Member of the Editorial board of The Open Clinical Cancer Journal, Bentham Science, dal 2013 ad oggi.

Member of the Editorial board of Blood Cancer Journal (ISSN: 2044-5385), Bentham Science, dal 2013 ad oggi.

Websites

– ASCO 2012 review for EANO – Primary CNS lymphoma
Sito dell’European Association of Neuro-Oncology, 2012

– e-grandround GR246: “New CNS Profilaxis and treatment in Nodal NHL. Evidence based recommendations”, Learning programmes on the Internet organized by the European School of Oncology, 2013

– e-grandround: “Treatment of diffuse large B-cell lymphomas” Learning programmes on the Internet organized by the European School of Oncology, 2014

– Co-author of texts on Lymphomas, Hodgkin’s Lymphoma and non Hodgkin’s Lymphomas for the website www.ultraspecialisti.com, 2017

Insalutenews, 22 maggio 2019

Linfoma follicolare, trattato il primo paziente in Italia con terapia CAR-T

Per la prima volta in Italia un paziente affetto da linfoma follicolare refrattario alle terapie convenzionali è stato trattato con le cellule CAR-T anti-CD19, una terapia cellulare avanzata che si basa sull’ingegnerizzazione dei linfociti T del paziente per aiutarli a riconoscere e aggredire le cellule tumorali… Continua a leggere su In salute news


LaRepubblica, 6 settembre 2019

CAR-T: al via, anche in Italia, la sperimentazione sul linfoma follicolare

SI APRE in Italia un nuovo studio che vuole dimostrare l’efficacia della terapia a base di linfociti T modificati: questa volta a essere nel mirino dei CAR-T è il linfoma follicolare. Dopo la leucemia linfoblastica acuta e il linfoma diffuso a grandi cellule B, malattie per le quali la tecnologia che modifica le cellule del sistema immunitario rendendole capaci di annientare quelle cancerose ha già dimostrato di essere efficace, potrebbe quindi essere il turno del linfoma follicolare… Continua a leggere su LaRepubblica


Insalutenews, 22 maggio 2019

Linfoma primitivo del sistema nervoso centrale, rapida regressione della malattia con farmaco sperimentale

Un farmaco antitumorale sperimentale dimostra oggi la sua sicurezza e i primi segni di efficacia nel trattamento dei linfomi primitivi del sistema nervoso centrale, tumori del sangue altamente aggressivi che rimangono confinati all’interno del cervello e che oggi mancano di una terapia efficace… Continua a leggere su In salute news


PharmaStar, 3 luglio 2018

Terapie onco-ematologiche, cosa fare con le infezioni fungine invasive?

Le sfide nella gestione del paziente con malattie ematologiche maligne e immunocompromesso sono oggi molto più complesse, anche a causa dell’uso dei nuovi farmaci biologici e immunomodulanti che, sebbene diano al malato possibilità di cura un tempo solo sperate, hanno nettamente modificato l’incidenza e l’epidemiologia delle complicanze infettive. Per affrontare questo tema in un incontro di due giorni si sono riuniti a Milano i rappresentati delle società scientifiche impegnate in ematologia… Continua a leggere su PharmaStar


Osservatorio malattie rare, 19 giugno 2018

Linfoma cerebrale, nuovi dati sul potenziale terapeutico di NGR-hTNF

MolMed S.p.A., azienda biotecnologica focalizzata su ricerca, sviluppo, produzione e validazione clinica di terapie geniche e cellulari per la cura di cancro e malattie rare, annuncia che nuovi e importanti dati relativi all’agente terapeutico proprietario NGR-hTNF nei linfomi cerebrali sono emersi dallo studio indipendente “INGRID” presentato durante la sessione “Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia" di ASCO, il convegno annuale dell’American Society of Clinical Oncology a Chicago, dal Dr. Andrés J. M. Ferreri, Responsabile dell’Unità Linfomi, IRCCS Ospedale San Raffaele di Milano, primo firmatario della ricerca… Continua a leggere su Osservatorio malattie rare


Lymphoma Hub, June 2019
Trattamento del linfoma primario SNC

Lymphoma Hub, January 2018
Trattamento del linfoma primario SNC

How to apply for an online medical consultation

Register your details in the secure area and choose the doctor according to your disease.

Fill in the medical history form and upload your reports and clinical exams.

Enter your billing information and make the payment.

Within 5 working days you will receive the doctor’s online consultation.